Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertinib for malignant pleural effusion (MPE) remains understudi...

Full description

Bibliographic Details
Main Authors: Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Thoracic Cancer
Subjects:
EGFR
malignant pleural effusion
non‐small cell lung cancer
osimertinib
Online Access:https://doi.org/10.1111/1759-7714.15210

Internet

https://doi.org/10.1111/1759-7714.15210

Similar Items